Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > Tohru Hasegawa

<< Previous

Bullboard Posts

Next >>

Comment by Mole101on Apr 02, 2021 7:59pm

86 Views

Post# 32932946

RE:RE:RE:RE:Tohru Hasegawa

The horse is running loose out of his barn and wants to kick somebody !!.. or maybe needs to average down from his I know it and this how it is Billion dollar dream company !

quote=BitHorse]I'M GUESSING YOU DIDN"T GET THE MEMO? BECAUSE...

These 2 people have already met with the Biopub subscribers and provided them with an update on the way forward since the Topline data was released. Do you think that's a fact or fiction? If it's not fiction - then what are you prepared to do about it other than bending over and taking 3rd place behind a group of paid subscribers to a Medical and Scientific Advisor Board member (Dr. Mark Swaim, MD, PhD) at Algernon Pharmaceuticals? So they have already talked to 2 doctors who can answer your questions along with the CEO (Christopher J. Moreau). The conflicts of interest are endless at AP and it appears none of you want to do anything about it. It's your money and your voice. Look in the mirror and decide what type of investor you wanna be. Half @ssed and @ssed out.